phase I trial

A phase I trial is the first time a candidate drug meets human biology under controlled conditions. Its overriding question is not whether the drug cures anything but whether it is safe enough to keep studying and what happens to it in the body. It is the cautious first handshake with the human organism, done in small numbers and with intense observation.

Most phase I studies enroll a few dozen healthy adult volunteers, who are dosed in small groups starting at a very low level. The dose is escalated step by step — single ascending doses, then multiple ascending doses — while the team watches for adverse events and draws blood to measure how the drug rises, distributes, and clears. This builds the first human pharmacokinetic picture and helps locate the maximum tolerated dose. For drugs too toxic to give to healthy people, such as cytotoxic cancer agents, phase I is run in patients instead.

Because the numbers are small and the volunteers are usually healthy, phase I cannot prove a drug works against disease, and rare side effects can slip through unseen. A clean phase I is necessary but far from sufficient: it opens the door to larger efficacy studies rather than guaranteeing success in them.